5 Firms Advise On Gilead's Up To $5B Tubulis Acquisition
By Al Barbarino · April 7, 2026, 12:01 PM EDT
Gilead Sciences Inc. said Tuesday it has agreed to acquire German clinical-stage cancer biotechnology company Tubulis for up to $5 billion, in a deal steered by five law firms....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login